CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,795,638 | +157.8% | 2,178,737 | +56.2% | 4.40% | +126.4% |
| Q2 2023 | $25,137,936 | +38.1% | 1,395,002 | +23.0% | 1.94% | +12.5% |
| Q1 2023 | $18,208,539 | +11.8% | 1,133,782 | +27.4% | 1.73% | -9.7% |
| Q4 2022 | $16,288,922 | +59.7% | 890,105 | +71.4% | 1.91% | +40.7% |
| Q3 2022 | $10,198,000 | – | 519,256 | – | 1.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $84,379,000 | 7.91% |
| RA Capital Management | 1,875,209 | $46,880,000 | 2.52% |
| Perceptive Advisors | 2,587,953 | $64,698,000 | 1.48% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $4,193,000 | 1.12% |
| Orbimed Advisors | 2,039,282 | $50,982,000 | 0.79% |
| Eventide Asset Management | 803,839 | $20,096,000 | 0.61% |
| Novo Holdings A/S | 135,009 | $3,375,000 | 0.47% |
| Opaleye Management Inc. | 36,000 | $900,000 | 0.27% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 490,000 | $12,250,000 | 0.03% |
| Baker Brothers Advisors | 132,985 | $3,325,000 | 0.02% |